Ningbo MedicalSystem Biotechnology Co Ltd
Medicalsystem Biotechnology Co., Ltd. engages in the research, development, production, and sales of in vitro diagnostic products in China. It is also involved in the provision of Three-party medical diagnosis services. The company offers automated chemistry analyzers; and automated chemiluminescence immunoassay analyzer; hematology analyzers and reagents; total laboratory automation system; mass… Read more
Ningbo MedicalSystem Biotechnology Co Ltd (300439) - Total Assets
Latest total assets as of September 2025: CN¥3.66 Billion CNY
Based on the latest financial reports, Ningbo MedicalSystem Biotechnology Co Ltd (300439) holds total assets worth CN¥3.66 Billion CNY as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Ningbo MedicalSystem Biotechnology Co Ltd - Total Assets Trend (2011–2024)
This chart illustrates how Ningbo MedicalSystem Biotechnology Co Ltd’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Ningbo MedicalSystem Biotechnology Co Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
Ningbo MedicalSystem Biotechnology Co Ltd's total assets of CN¥3.66 Billion consist of 49.2% current assets and 50.8% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 19.7% |
| Accounts Receivable | CN¥572.72 Million | 15.5% |
| Inventory | CN¥286.01 Million | 7.7% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥135.43 Million | 3.7% |
| Goodwill | CN¥0.00 | 0.0% |
Asset Composition Trend (2011–2024)
This chart illustrates how Ningbo MedicalSystem Biotechnology Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Ningbo MedicalSystem Biotechnology Co Ltd's current assets represent 49.2% of total assets in 2024, a decrease from 61.8% in 2011.
- Cash Position: Cash and equivalents constituted 19.7% of total assets in 2024, up from 19.5% in 2011.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 3.0% of total assets, an increase from 2.0% in 2011.
- Asset Diversification: The largest asset category is accounts receivable at 15.5% of total assets.
Ningbo MedicalSystem Biotechnology Co Ltd Competitors by Total Assets
Key competitors of Ningbo MedicalSystem Biotechnology Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
ADCNF
OTCGREY:ADCNF
|
USA | $4.51 Billion |
|
Berry Genomics Co Ltd
SHE:000710
|
China | CN¥2.34 Billion |
|
Malaysian Genomics Resource
KLSE:0155
|
Malaysia | RM20.70 Million |
|
NSN Co. Ltd
KQ:031860
|
Korea | ₩60.96 Billion |
|
JOONGANG DNM Co.Ltd
KQ:051980
|
Korea | ₩121.79 Billion |
|
GeneMatrix Inc
KQ:109820
|
Korea | ₩28.03 Billion |
|
Genoray Co. Ltd
KQ:122310
|
Korea | ₩125.67 Billion |
|
Green Cross Lab Cell Corporation
KQ:144510
|
Korea | ₩565.79 Billion |
Ningbo MedicalSystem Biotechnology Co Ltd - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Moderate asset utilization - Ningbo MedicalSystem Biotechnology Co Ltd generates 0.47x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Solid ROA - For every $100 in assets, Ningbo MedicalSystem Biotechnology Co Ltd generates $6.96 in net profit.
Ningbo MedicalSystem Biotechnology Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.12 | 3.07 | 1.13 |
| Quick Ratio | 2.70 | 2.62 | 0.95 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥1.28 Billion | CN¥ 1.21 Billion | CN¥ 180.40 Million |
Ningbo MedicalSystem Biotechnology Co Ltd - Advanced Valuation Insights
This section examines the relationship between Ningbo MedicalSystem Biotechnology Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.36 |
| Latest Market Cap to Assets Ratio | 0.08 |
| Asset Growth Rate (YoY) | 6.2% |
| Total Assets | CN¥3.71 Billion |
| Market Capitalization | $283.14 Million USD |
Valuation Analysis
Below Book Valuation: The market values Ningbo MedicalSystem Biotechnology Co Ltd's assets below their book value (0.08 x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Ningbo MedicalSystem Biotechnology Co Ltd's assets grew by 6.2% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Ningbo MedicalSystem Biotechnology Co Ltd (2011–2024)
The table below shows the annual total assets of Ningbo MedicalSystem Biotechnology Co Ltd from 2011 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥3.71 Billion | +6.19% |
| 2023-12-31 | CN¥3.49 Billion | -2.64% |
| 2022-12-31 | CN¥3.58 Billion | -0.26% |
| 2021-12-31 | CN¥3.59 Billion | +10.42% |
| 2020-12-31 | CN¥3.25 Billion | -13.01% |
| 2019-12-31 | CN¥3.74 Billion | -18.62% |
| 2018-12-31 | CN¥4.60 Billion | +7.44% |
| 2017-12-31 | CN¥4.28 Billion | +25.17% |
| 2016-12-31 | CN¥3.42 Billion | +136.26% |
| 2015-12-31 | CN¥1.45 Billion | +132.89% |
| 2014-12-31 | CN¥621.25 Million | +31.92% |
| 2013-12-31 | CN¥470.92 Million | +42.17% |
| 2012-12-31 | CN¥331.23 Million | +84.88% |
| 2011-12-31 | CN¥179.16 Million | -- |